News ImmuneRegen NewsImmuneRegen BioSciences Appoints Dr. Paul Carlton to Bioterrorism Preparedness Advisory BoardMarch 14, 2005 10:59:00 AM ETHomeland Security Official/Former Air Force Surgeon General Joins Board as Sr. Advisor SCOTTSDALE, Ariz., March 14 /PRNewswire/ -- Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), has named former Air Force Surgeon General Paul K. Carlton, Jr., M.D., Lt. General, USAF (Ret.) as Senior Advisor to its recently established Bioterrorism Preparedness Advisory Board. Dr. Carlton currently serves as Director to the Office of Homeland Security for the Texas A&M University System Health Science Center. The U.S. Food and Drug Administration (FDA) and the Department of Counter Terrorism (DCT) has requested that ImmuneRegen form the board to develop an emergency deployment plan for ImmuneRegen's proprietary compound, Radilex™. Having undergone its seventh stage of testing, Radilex™ is a treatment currently in development to counteract the effects of lethal radiation exposure, anthrax or ricin poisoning, as well as similar inhalants. "Winning the war on terrorism and assuring the future of our country is dependent on our ability to think differently and to be as innovative as possible," remarked Dr. Carlton. "For that reason, I was very interested in joining the ImmuneRegen advisory board. Their compound, Radilex™, shows great potential in modulating the immune response system with obvious applications to bioterrorism and also to a wider range of auto-immune diseases." Dr. Carlton will be charged, along with his fellow board members, with developing a plan to disseminate the proprietary and potentially life-saving Radilex™ in the event of a biological or nuclear disaster. In this respect, Dr. Carlton will be assisting Dr. Mark Witten, Advisory Board Chairman and ImmuneRegen BioSciences Chief Scientific Officer and Founder. Other members of the Bioterrorism Preparedness Advisory Board include Dr. William E. Hoehn, a legislative and executive veteran of the federal government and a researcher and think tank executive as well as Michael Caridi, a security industry entrepreneur and major real estate developer. "It's a great honor to have someone of Dr. Carlton's stature join our board," said Michael Wilhelm, ImmuneRegen's CEO. "As the former Surgeon General of the Air Force, he comes to us with a wealth of experience in large-scale logistics for emergency medical services. His background is ideal for our mission to massively deploy Radilex™ in case of a national bioterrorism disaster." More About Dr. Carlton Paul K. Carlton, Jr. received his Bachelor of Science degree for the U.S. Air Force Academy in 1969 and his doctor of medicine from the University of Colorado in 1973. Dr. Carlton serves as Director to the Office of Homeland Security for The Texas A&M University System Health Science Center. He joined the Texas A&M Faculty in November of 2002. Dr. Carlton also served as the Surgeon General of the Air Force from 1999 to 2002. As the Surgeon General of the Air Force, he served as a functional manager of the U.S. Air Force Medical Service. He had authority to commit resources worldwide for the Air Force Medical Service to make decisions affecting the delivery of medical services and to develop plans, programs and procedures to support peacetime and wartime medical service missions. Dr. Carlton is a fellow and former Air Force governor of the American College of Surgeons. He was named a consultant in general surgery to the Air Force Surgeon General in 1981. He conceptualized and implemented the first Air Force rapid-response surgical team in Europe -- the flying ambulance surgical trauma team. During Operation Desert Storm, he commanded the 1702nd Air Refueling Wing Contingency Hospital, completing 32 combat support missions and 140 combat flying hours in the C-21, C-130, KC-10 and KC-135. He has published extensively in medical literature. He is an 11,000 case surgeon who continues to "wash his hands" whenever he can. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|